Rare Disease Day Roundup 2022

This past February 28th marked  Rare Disease Day (RDD) 2022, the globally-coordinated movement on rare diseases, which works towards equity in social opportunity, healthcare, and access to diagnosis and therapies for people living with a rare disease; the NMD4C would like to take this opportunity to share some of the campaigns and events hosted by members of the neuromuscular community for this year’s event.


Muscular Dystrophy Canada

To celebrate RDD MDC hosted an “Individually  Rare, Collectively Common” campaign, spotlighting Canadians affected by different neuromuscular disorders (NMDs) and asking them the question: ‘what do you wish you knew when you were first diagnosed and how have you advocated for yourself along the way?’ Read the responses from Canadians affected by NMDs in this article on MDC’s website!


Defeat Duchenne Canada

Defeat Duchenne Canada (formerly Jesse’s Journey) asked for the help of the Duchenne community in raising awareness of Duchenne muscular dystrophy on Rare Disease Day, through their social media campaign. You can see how they raised awareness online by:

  1. Following @defeatduchenne on Facebook, Twitter, Instagram, and LinkedIn
  2. View and share their posts from Monday, February 28th, as Duchenne ambassadors speak to what it’s like living with a rare disease.



To raise awareness for GNE myopathy, the ProDGNE consortium shared a week-long #GNEMfacts campaign in the lead-up to RDD to raise awareness of this ultra rare disease. Curated by communications lead and Patient Representative at Gli Equilibristi HIBM Michela Onali, the campaign shares facts describing the clinical aspects of GNE myopathy, challenges in diagnosis and care, and GNE myopathy research. 


Check out the video below to learn more about the ProDGNE consortium, which aims to advance the steps for impactful research in GNE Myopathy by expanding the GNE Myopathy research network and building a long term partnership where patients are central partners and key drivers in Research and Development. You can also visit ProDGNE’s website to learn more. 


Myotonic Dystrophy Foundation

The Myotonic Dystrophy Foundation (MDF) is celebrating RDD by continuing their advocacy for people affected Myotonic dystrophy (DM1) to have equal social opportunity, non-discrimination in education and work, and equitable access to health, social care, diagnosis and treatment. MDF have shared a web page where you can access tools to empower advocacy for DM1, learn about possible clinical trials, join the Myotonic Dystrophy Family Registry, and Dm1 guidelines and publications.

This past year MDF recognized the inaugural International  Myotonic Dystrophy Awareness Day on September 15th, in partnership with the members of the global alliance including the NMD4C and MDC. Learn more about MDF’s plans for this year’s event here.



Facioscapulohumeral muscular dystrophy (FSHD) Society

The FSHD Society have prepared a web page with helpful resources  to join the chorus of FHSD community members telling their story on RDD and beyond, including ways to connect online, joining events, and staying informed by signing up for email updates and following the FSHD blog!


Charcot-Marie-Tooth Association

The Charcot-Marie-Tooth (CMT) Association launched a #ImNotGoingToApologizeFor campaign on social media to celebrate RDD. See the campaign below, and learn about how people affected by CMT overcome challenges associated with the disease.

Rare Disease Day logo

Read next...

2024 Dr David Green Award winners from MDC

NMD4C Receive Excellence in Service Delivery Award and Network Investigators Honored as part of Muscular Dystrophy Canada’s 2024 Dr David Green Awards

We are excited to share that the NMD4C has been awarded the Excellence in Service Delivery Award, one of the annual Dr David Green Awards presented by Muscular Dystrophy Canada.

NMD4C logo with text reading 'Canadian neuromuscular clinical trials network', MDC and IMHA logos at bottom.

NMD4C Launch Canadian Neuromuscular Clinical Trial Network

We are thrilled to announce the launch of a Canadian neuromuscular clinical trial network (CTN) as a part of our clinical research work.

Event organizers and participants from SMA outcome measures training, March 2024 in Quebec.

Training Session for Physiotherapists and Occupational Therapists on Outcome Measures in Spinal muscular atrophy hosted by Quebec SMA Network

This past March 23, the Quebec SMA Network (Réseau québécois de l’amyotrophie spinale – RQAS) in collaboration with the NMD4C and Muscular Dystrophy Canada (MDC) hosted an interactive training session for French-speaking physiotherapists and occupational therapists on assessment measures and practices for Spinal muscular atrophy (SMA). This training gathered clinicians to train and discuss SMA standardized outcome measures and work through current problems/challenges, to improve how these measures often tied to drug reimbursement are conducted. 

MDC award $900 000 towards clinical and translational research projects in 2024.

MDC Announce Recipients of 2024 Neuromuscular Clinical and Translational Research Grants

Muscular Dystrophy Canada (MDC) recently announced the recipients of its annual Neuromuscular Research Grants competition. Through these grants, MDC is investing $900,000 into clinical and translational research projects.

SMA outcome measures training graphic

SMA Outcome Measures Training for Physiotherapists and Occupational Therapists

To support the development and training on validated NMD outcome measures we are pleased to provide opportunities for physiotherapists and occupational therapists to attend training sessions for outcome measures.

Congratulations to the 2024 early career award winners. Dr Mireille Khacho and Dr Jean-Philippe Leduc Gaudet.

Congratulations to the 2024 NMD4C Early Career Awards Recipients

We are excited to announce the recipients of the 2024 NMD4C Early Career Awards! This is the second year of our annual award program, celebrating excellence and contribution to the neuromuscular field from early career investigators across both clinical and basic science streams.